1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C5C64DBA5F515832852572C00066FF03
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/scientific-publications-strategy-managing-reputation-clinical-trial-results-and-commercial-relevance?opendocument
18
19opendocument
2018.205.246.238
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance

ID: PSM-220


Features:

10 Info Graphics

8 Data Graphics

200+ Metrics

18 Narratives

36 Best Practices


Pages: 87


Published: Pre-2013


Delivery Format: Shipped


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
During the past few years, scientific journals and government regulators have increased the scrutiny and expectations facing pharmaceutical companies looking to publish the results of their clinical trials. With this scrutiny has come a shift in focus and transparency. Gone are the days of picking and choosing favorable findings to share, but now companies are struggling with how to measure the success of their Scientific Publications groups. With ever-changing expectations and regulations, global publications leaders at pharmaceutical companies must carefully build their strategies to present findings in an ethical and transparent manner.


Best Practices conducted this research in 2011 and 2007 and you will see longitudinal data where appropriate. This will allow you to see how trends in Scientific Publications have evolved in the last four years.


Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical Device; Health Care; Biotech; Diagnostic


Companies Profiled:
Alkermes; Astellas; Baxter; Becton Dickinson; Boehringer Ingelheim; Cephalon Epigenomics; Ethicon; GlaxoSmithKline; Human Genome Sciences; Janssen; Lundbeck; Novartis; Novo Nordisk; Theravance; URL Pharma


Study Snapshot

This research was launched to determine how leading pharmaceutical and biotechnology companies are shaping their global publications strategies and plans in order to maintain scientific credibility while also delivering commercially relevant publications that drive brand success.

This study was conducted through surveys and qualitative interviews with pharmaceutical and biotechnology Global Publication Strategy executives. The benchmark class includes 17 participants from 16 companies across the pharmaceutical, biotech and medical device industries.

Key topics include:
  • Optimal structure for the global publications function
  • Transition of global pub function from commercial to clinical
  • Key internal stakeholders who contribute to publications strategy
  • Tactics for handling publication of neutral or negative clinical trial results
  • Impact of transparency guidelines on publications, planning and delivery
  • Strategy changes for the new marketplace

Sample Key Findings

Future Changes in Publication Environment: In 2011, 3 out of 4 benchmark partners include scenario planning for publishing clinical trials. Results in case of neutral or negative results. As compared to 33% of benchmark class in 2007, 50% of research partners in 2011 plan to increases emphasis on regional peer-reviewed journals in next year. However, 30% of benchmark companies plan to decrease their emphasis on e-journals in 2011. In coming 3 years, 45% of benchmark class plans to stress on review articles for market preparation while 4 out of 10 participants will increase their emphasis on global and regional peer-reviewed journals for greater transparency.
  • Global Peer-Reviewed Publications Most Effective Publication Vehicle During Phase III & Post Launch: Relative to 2007, global peer-reviewed publication as most effective vehicle has dropped by 46%. Consequently, an equal 46% of benchmark partners consider global peer-reviewed publication as most effective during phase-III and post launch. Relative to 2007, during early product development phases 20% of respondents consider specialty journals as most effective vehicle, while during phase-III 27% lesser benchmark class partners deem specialty journals as most effective vehicle for publication.
Table of Contents

INTRODUCTION 4
Project Methodology and Study Objective 5
SUMMARY OF KEY INSIGHTS 6-14
UNIVERSE OF LEARNING 15
List of Participating Companies 16
Range of Career Levels Lend Insight 17
Regional Representation 18
Functional Representation 19
Those Who Work for Publications Mostly Have Ph.D. 20
Respondents Serve Various Therapeutic Areas in Publication Function 21
Current Role With Regards To Publication 22
Mostly Vice President Oversee Publication Function 23
GLOBAL PUBLICATION ORGANISATION 24
Publication Function Is A Part Of Medical Affairs Group 25
Publication Strategy Shifting To Hybrid Structure 26
Strategy Responsibility 27
Publications Planning Shifting To Hybrid Structure 28
Planning Responsibility 29
Centralized Structure Followed for Publications Plan Delivery 30
Plan Delivery Responsibility 31
Medical Directors Mainly Contribute to Strategy & Plan 32
Other Strategy Contributors 33
Successful Communication Tactics 34
Top Tactics Used to Communicate Publication Strategy 35
Regional Empowerment 36
Alignment Between the Regional & Global Plans 37
Plan Delivery Outsourcing 38
FTEs in Publication Function 39
Percent Publications FTEs Outsourced 40
Tasks Outsourced by Publication Group 41-43
PUBLICATION STRATEGIES BY PRODUCT 44
Most Effective Publication Vehicle in Early Development 45
Most Effective Publication Vehicle in Phase III-Submission 46
Most Effective Publication Vehicle in Launch-Post-Launch 47
Most Effective Content Type in Early Development 48
Most Effective Content Type in Phase III-Submission 49
Most Effective Content Type in Launch-Post-Launch 50
Most Important Target Audience in Early Development 51
Most Important Target Audience in Phase III-Submission 52
Most Important Target Audience in Launch-Post-Launch 53
Publications Outlet Focus 54-56
Development of Publishing Strategy 57
Stage of Publishing First Abstract & Manuscript 58
Last Stage When Publication Function is Active 59
Publication Produced 60
Abstracts Produced 61
Number of Manuscripts Planned, Produced & Published 62
Number of Publications Issued 63-64
Mix of Papers Appearing 65
MEASURING THE EFFECTIVENESS OF PUBLICATION STRATEGY ACTIVITIES 66
Performance Measures 67-68
Paper Acceptance Most Important Measure of Effectiveness 69
Primary Journals Highly Important for Publishing Clinical Results 70
MANAGING WITHIN A CHANGING PUBLICATION ENVIRONMENT 71
Planning Neutral or Negative Results 72
Process for Publishing Neutral and Negative Results 73
Increased Emphasis on Regional-Peer Reviewed Journals 74
Emphasis on E-journals Will Decline 75
Increased Importance of Review Articles Over Next Three Years 76
Other Changes Implemented for Publication Excellence 77
PUBLICATION BUDGET 78
Budget Allocated 79
Allocation of Publication Budget in Various Activities 80
Medical Affairs Funds Publication Budget 81
Factors Affecting Publication Budget 82
PUBLICATION BEST PRACTICES 83
Top Best Practices for Publication Effectiveness 84
Top Challenges 85
Best Practices for Implementing Successful Scientific Publication Strategy 86